RESEARCH TRIANGLE PARK, N.C. & TORONTO--(BUSINESS WIRE)--Talecris Biotherapeutics, Inc. announced today that the company has been selected by Canadian Blood Services and Héma-Québec as the primary fractionator for Canadian plasma and the primary supplier of immune globulin intravenous (IGIV) during the next five years. This contract, beginning April 1, 2008, designates Talecris as the primary supplier of immune globulin intravenous (IGIV) through its product Gamunex® (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified), and a range of other commercial plasma products.
